Phoenix A. Ho

Hematology | Oncology
2324 Eastlake Ave E Ste 500
Seattle, WA 98102

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.

A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.

Journal: British journal of haematology
Published: September 12, 2018

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Journal: Blood
Published: March 28, 2018

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Journal: Blood
Published: June 12, 2017

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Journal: Haematologica
Published: May 16, 2016

FAM111B Mutation Is Associated With Inherited Exocrine Pancreatic Dysfunction.

FAM111B Mutation Is Associated With Inherited Exocrine Pancreatic Dysfunction.

Journal: Pancreas
Published: October 27, 2015

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.

Journal: Pediatric blood & cancer
Published: October 31, 2014

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Journal: British journal of haematology
Published: February 21, 2013

The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.

The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.

Journal: Pediatric blood & cancer
Published: January 07, 2013

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Journal: Leukemia
Published: June 23, 2012

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

Journal: Blood
Published: June 01, 2012

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Journal: Blood
Published: March 02, 2012

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Journal: Blood
Published: August 30, 2011
Showing 1-12 of 15

Last Updated: 09/26/2026